Cognition and Pain: A Review
Tanvi Khera and Valluvan Rangasamy*
Department of Anesthesia Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States

Cognition is defined as the brain's ability to acquire, process, store, and retrieve information. Pain has been described as an unpleasant sensory or emotional experience, and for experiencing pain consciously, cognitive processing becomes imperative. Moreover, evaluation of pain strongly depends on cognition as it requires learning and recall of previous experiences. There could be a possible close link between neural systems involved in cognition and pain processing, and studies have reported an association between pain and cognitive impairment. In this narrative review, we explore the available evidence that has investigated cognitive changes associated with pain. We also examine the anatomical, biochemical, and molecular association of pain and neuro-cognition. Additionally, we focus on the cognitive impairment caused by analgesic medications. There is a need to improve our understanding of pathophysiology and cognitive impairment mechanisms associated with chronic pain and its treatment. This area provides a diverse opportunity for grounding future research, aiding institution of timely interventions to prevent chronic pain and associated cognitive decline, ultimately improving patient care.

Keywords: cognition, pain, memory, cognitive behavior therapy, chronic pain

INTRODUCTION
The multidimensional pain experience is a prevalent complaint in clinical practice and impacts an individual's physiologic and psychologic states. Pain is classically defined as an unpleasant sensory or emotional experience associated with actual or potential tissue damage (Raja et al., 2020). Thus, pain is a subjective perceptual phenomenon involving cognitive processing rather than a purely sensory phenomenon (Casey and Lorenz, 2000). Cognition involves the acquisition, processing, storage, and retrieval of information by the brain (Lawlor, 2002). Cognition is composed of critical elements such as attention, perception, memory, motor skills, executive functioning, and verbal and language skills (Gellman and Rick Turner, 2013). Cognition is a vital component of the subjective perception of pain requiring cognitive-evaluation, learning, recall of past experiences, and active decision making (Hansen and Streltzer, 2005; Moriarty et al., 2011). The key aspects of learning and memory require attention, which is enhanced by adding an emotional component to the process (Tyng et al., 2017). Multiple cortical and subcortical brain areas are involved in perception, processing, relaying, and pain modulation. Increasing evidence of the close association between neural systems of cognition and pain shows a bi-directional modulatory role.

Observations in the setting of chronic pain (pain persisting longer than 3 months) usually exceed the duration of the noxious stimulus and have deleterious effects on the psychosocial elements of the individual (Hart et al., 2000; Treede et al., 2019; Walankar et al., 2020). Although chronic pain has long been shown to alter cognitive outcomes, emerging studies over the past decade have drawn...
The thalamic reorganization is an essential pathway for the motivational and affective domains of pain (Bourne et al., 2014), and the medial thalamic nuclei are important components of the hypothalamus, and higher cortical centers. These projections of the thalamic projections relay to brainstem reticular formation, the posterior nucleus and the central nucleus of the thalamus. Later, sensations run along the ventrolateral spinal cord to the ventral horn, where the sensory input is transmitted to the central nervous system (CNS; Bourne et al., 2014). In the event of persistent noxious stimulation, there is an upregulation of A-fibers to perceive pain in addition to C fibers; this is responsible for central sensitization leading to hyperalgesia.

Noxious stimuli are transduced via a series of specialized nociceptors into a recognizable signal, transmitted through Aδ (touch, temperature), and C fibers (pain). Most sensory fibers would then project to the dorsal root ganglion (DRG), from where the sensory input is transmitted to the central nervous system (CNS; Bourne et al., 2014). In the event of persistent noxious stimulation, there is an upregulation of A-fibers to perceive pain in addition to C fibers; this is responsible for central sensitization leading to hyperalgesia.

Primarily, C fibers contribute to modulation at the level of DRG by regulating the N-methyl-D-aspartate (NMDA) receptor configuration and sensitivity (Neumann et al., 1996). An additional modulation of the ascending pain occurs at the spinal cord level through the release of gamma-aminobutyric acid. Functional loss of the lamina II has been implicated in the development of chronic neuropathic pain (Bourne et al., 2014). The spinothalamic tracts transmitting pain and temperature sensations run along the ventrolateral spinal cord to the ventral posterior nucleus and the central nucleus of the thalamus. Later, the thalamic projections relay to brainstem reticular formation, hypothalamus, and higher cortical centers. These projections to the reticular formation, periaqueductal gray matter (PAG), and the medial thalamic nuclei are important components of motivational and affective domains of pain (Bourne et al., 2014). The thalamic reorganization is an essential pathway for the development of central pain and neuropathic pain. There is an extensive cortical neural circuitry involved in the perception, localization, and modulation of painful stimuli. This network mostly consists of medial and lateral pain systems. The median system consists of the anterior cingulate cortex (ACC), the insular cortices, and the lateral system consisting of primary (SI) and the secondary somatosensory (SII) cortices. Other cortical areas involved in pain perception are the ventrolateral orbital cortex and the motor cortex (Xie et al., 2009).

The descending pain pathway comprises various supraspinal components – the rostral ventromedial medulla (RVM), the dorsolateral pontomesencephalic tegmentum, and the PAG (Bourne et al., 2014). The PAG-RVM-DH (Dorsal horn) pathway is called the descending pain modulatory pathway. In the limbic system, amygdala is associated with the emotional-affective component of pain and modulation thereof. It is activated in response to noxious stimuli, thus lending the amygdala’s central nucleus the name “nociceptive amygdala” (Neugebauer, 2015). The interconnection between the amygdala and the prefrontal cortex, cingulate cortex, basal ganglia, and the cortico-limbic reverberating loops is implicated in chronic pain conditions such as chronic regional pain syndrome (CRPS), visceral hypersensitivity in irritable bowel syndrome (IBS), chronic pelvic pain (Thompson and Neugebauer, 2017). Monoamines, serotonin (5-HT), dopamine (DA), and norepinephrine (NE) help with modulation of the descending pathway by predominantly acting on lamina I and II of the spinal cord. Dysregulated descending modulation plays a vital role in chronic pain conditions (Bourne et al., 2014).

### Neuroplasticity and Chronic Pain

Neuroplasticity includes the structural and functional changes that occur in the brain enabling adaptation to environmental cues, learning, memory, and rehabilitation after brain injury (Gulyaeva, 2017). In fact, it is the neurochemical basis of memory formation (Joshi et al., 2019). Neuroplasticity in the context of pain refers to the changes that alter an individual’s response to pain by the development of either chronic pain or hypersensitivity (Basbaum et al., 2009; Gulyaeva, 2017). Neuroplastic adaptations of the brain to chronic pain lead to modulation of cognitive domains, affecting the pain perception. Imaging studies have suggested a spatiotemporal reorganization of brain activity in relation to chronic pain, during which the representation of pain gradually shifts from sensory to emotional and limbic structures. Thus, the transition of acute pain to chronic pain is a type of activity-induced plasticity of the limbic-cortical circuitry resulting in the reorganization of the neocortex (Thompson and Neugebauer, 2017). Evidence suggests the relationship of the medial prefrontal cortex (mPFC) in the cortico-limbic interaction for modulation of response at the amygdala level. This may offer novel techniques for the control of pain by engaging mPFC control of the amygdala. There is an inter-individual difference in the encoding of painful stimuli and generation of memory for
Khera and Rangasamy

Cognition and Pain: A Review

FIGURE 1 | Ascending and descending pain signaling and modulation of pain at each level. Inset shows a schematic of cortical modulation of pain. PAG, Periaqueductal gray; RVM, Rostral ventral medulla; DRG, Dorsal root ganglion; NSAIDs, Non-steroidal anti-inflammatory drugs; SNRI, Serotonin and norepinephrine reuptake inhibitor; SI, Primary somatosensory cortex; and SII, Secondary somatosensory cortex. The schematic art pieces used in this figure were provided by Servier Medical art (http://servier.com/Powerpoint-image-bank). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License. Cortical modulation schematic adapted from Xie et al. (2009).

These experiences. This inter-individual difference is based on how the noxious versus the innocuous stimuli are handled and shaped by the individual’s anxiety level. The medial thalamus and ACC are responsible for encoding the stimuli as painful, and the somatosensory cortex discerns non-painful stimuli. This encoding process is also associated with enhanced functional connectivity between the thalamus and the mPFC and is essential to the affective component of pain perception and memory formation (Tseng et al., 2017).

Various neurotrophic factors, neuro-modulatory lipids, and neuropeptides are implicated in the development of plasticity (Duric and McCarson, 2006; Doan et al., 2015). Neuropeptides such as NE, DA, and 5-HT are essential in modulating descending pain signals and the affective component of pain, which is often linked to depression. Similarly, brain-derived neurotrophic factors (BDNF) are associated with the development of synaptic plasticity and de novo neurogenesis throughout the peripheral and central pain circuits. Decreased BDNF levels at the hippocampus are found in chronic pain conditions, and this finding is positively linked to the development of depression-like symptoms (Duric and McCarson, 2006; Doan et al., 2015).

A classic example of neuroplasticity in chronic pain setting is neuropathic phantom limb pain (Ramachandran and Rogers-Ramachandran, 2000). Its central pathophysiology involves the complex interaction of cortical elements, memory, and pain perception. Modalities such as non-invasive brain stimulation (NIBS) and cognitive-behavioral therapies (CBT) have shown positive effects in the treatment of neuropathic pain, reinforcing the role of cognition, and cortical perception in the pathophysiology of pain (Kikkert et al., 2019).

Repetitive noxious stimuli often lead to the development of a maladaptive change at the CNS level. This maladaptive change, called the “wind-up phenomenon” or central sensitization, is responsible for developing chronic intractable pain or non-responsive pain (Müller, 2000). This manifests either as hyperalgesia or allodynia. Hyperalgesia, where mildly noxious stimuli are perceived as painful due to resetting of the peripheral nerve threshold. Whereas, in allodynia, there is a recruitment of nerves that carry non-noxious impulses to pain-sensing neurons. Thus, a non-noxious stimulus is perceived as a noxious stimulus in allodynia. Additionally, the spontaneous firing of the DRG may add to the wind-up phenomenon (Gottin et al., 1995; Wilder-Smith, 1995). When sensory stimuli act on modified central neural mechanisms, the output is influenced by the memory of these painful stimuli (Melzack et al., 2006). The preemptive analgesia concept focuses on preventing the wind-up phenomenon. This is often achieved by blocking the peripheral transmission of pain by local anesthetics and central perception by using opioids and NMDA receptor antagonists (Gottin et al., 1995; Müller, 2000). There is growing interest in the use of preemptive analgesics in the surgical context. However, various authors have conflicting opinions about the use of preemptive analgesics for surgical patients (Gottin et al., 1995; Wilder-Smith, 1995).
CLINICAL EVIDENCE FOR PAIN AND COGNITION

A bi-directional relationship exists between cognition and pain (Villemure and Bushnell, 2002). Disruption of cognitive processing has been investigated in various common chronic pain syndromes, with studies focusing on several cognitive output types. Fibromyalgia, migraine, chronic back pain, rheumatoid arthritis, diabetic neuropathy, osteoarthritis, CRPS, peripheral neuropathic pain syndromes, and multiple sclerosis have been the focus of most clinical studies (Calandre et al., 2002; Dick and Rashiq, 2007; Cousins et al., 2015; Gil-Gouveia et al., 2015; Curatolo et al., 2017; Huang et al., 2017; Jensen et al., 2018; Martinson et al., 2018; Alemanno et al., 2019; Said et al., 2019; Oläh et al., 2020). Major cognitive parameters investigated encompass attention, learning, memory, sustained concentration, processing speed, psychomotor ability, and executive function Figure 2.

The methodologies employed in these studies comprise a battery of tests, which typically include pain questionnaires such as numerical rating scales, visual analog scales, or McGill pain questionnaire to measure pain, coupled with tests of cognition. Cognitive function may be assessed using subjective self-report measures or objectively with formal, empirically validated neuropsychological tests focusing on one or more aspects of cognition. To provide objectivity to the diagnosis, predicting therapeutic benefits of individualized interventions for chronic pain, the use of fMRI signatures is being investigated. This neural circuit potentially includes the thalamus, anterior and posterior cingulate cortex, and PAG (Wager et al., 2013). Analyzing the change in these signatures over time and with treatment can help pave way for personalized medicine in the future (Thorp et al., 2018). Comorbid affective disorders (such as depression and anxiety) and the effects of sleep disturbance and medication use are sometimes, but not always, considered, and they present an interesting dichotomy in the experimental approach.

Attention
Attention is the individual's capacity to process information and involves focused or directed consciousness (Mirsky et al., 1991). A diffuse system of interconnected neurons controls attention at the most fundamental level called the attention matrix. This system receives intrinsic and extrinsic sensory input continually, ultimately impacting the functional adaptations. Attention is a function of cortical and subcortical gray matter structures globally, with interconnected white matter tracts. The frontal lobe and inputs from a widespread network of thalamic and bihemispheric structures are the essential component of the attention neural networks (Filley, 2002). There is an overlap between the pain pathways and attention matrix, which makes the study of attention in pain and the modulation particularly interesting. LeGrain et al. (2009) suggested that continued painful stimuli impact attentional control mechanisms required to remove task-relevant stimuli, resulting in decreased task performance. In experimental studies, attention is evaluated based on attention span, attention switching between ≥2 cognitive tasks, and divided attention, which studies the ability to process >1 source of information simultaneously (Moore et al., 2019).

Young adults and middle-aged adults can use cognitively demanding tasks to diverge their attention and self-manage pain to some extent (Valet et al., 2004). Pain sensitivity is decreased with engagement in attention requiring tasks and with the use of environmental distractors (Sloan and Hollins, 2017; Hoegh et al., 2019). However, older adults are limited in this capacity, and chronic pain can impair independent living, a risk factor for physical disability, hospitalization, and death (van der Leeuw et al., 2018). Comorbidities such as depression and anxiety can impact both the perception of pain and attention (Shuchang et al., 2011). Thus, chronic pain patients, especially in the older age group with coexisting conditions, require special care in the clinical setting.

Clinical studies over the past decade have shown that there is an increased incidence of patient-reported attention deficits with chronic pain (McCracken and Iverson, 2001; Munoz and Esteve, 2005; van der Leeuw et al., 2018). The majority of the studies found no association between age, gender, pain-chronicity, anxiety, depression, medication, site of pain, and cognitive performance (Dick and Rashiq, 2007; Martinson et al., 2018). Interestingly, recent studies show decreased accuracy on attentional switching and divided attention tasks in patients with fibromyalgia (Moore et al., 2019). Animal models used to study the impact of pain on attention and learned behavior (operant nose poke tests) shows increased omissions and decreased accuracy in experimentally induced inflammatory pain (Boyette-Davis et al., 2008; Pais-Vieira et al., 2009). Due to heterogeneity in the chronic pain syndrome type, pain scales used, and cognitive tests for assessment of attention, it is difficult to draw definitive conclusions (Emerson et al., 2020; Rischer et al., 2020).

Memory
Conceptually, memory consists of a succession of storage systems essential for information flow from the environment to a short-term memory store, which then feeds long-term memory. The information about the environmental cues passes temporary sensory buffers en-route, which are essentially part of perceptual processes (Baddeley, 2010). Working memory is a subset of memory which controls this flow of information in and out of the long-term memory, thus playing an essential role in learning and cognition (Shiffrin, 1977). The hippocampus is associated with long-term explicit memory formation and handling emotional stressors (Zaletel et al., 2016; Sawangjit et al., 2018). Human and animal studies show a decreased hippocampal volume and structural and biochemical plasticity in the setting of chronic pain (Johnston et al., 2012; Mutso et al., 2012; Tajerian et al., 2018). Amygdala is another critical brain region for learning. The basolateral amygdala is activated in the presence of glucocorticoid, which impacts memory consolidation. Furthermore, working memory performance and retrieval are impaired with high glucocorticoid levels (Roozenaal et al., 2006). Involvement of the amygdala in chronic pain has now been shown in human studies and animal models for chronic pain, eliciting the influence of dorsal horn (DH)
neuron excitation and the interaction between the amygdala and the mPFC (Neugebauer et al., 2004; Ji et al., 2010). Studies over the past have demonstrated that chronic pain adversely affects working memory, recall, and recognition memory (McCracken and Iverson, 2001; Muñoz and Esteve, 2005; Berryman et al., 2013). Most patients with chronic pain report poor memory, recall, and concentration in their daily activities (Dufton, 1989; Iezzi et al., 1999, 2004; McGuire, 2013). Interestingly, implicit memory (semantic, procedural, and conditioned) is less likely to be affected by pain owing to its automated nature (Grisart and Van der Linden, 2001). Additionally, most studies concluded that patients with pain have deficits in general and specialized cognitive screening measures (Povedano et al., 2007; Rodriguez-Andreu et al., 2009). It is still unclear whether the intensity and nature of chronic pain syndrome impact semantic memory, immediate or delayed verbal memory, recognition memory, visuospatial memory, and long-term memory (Ryan, 2005; Weiner et al., 2006; Lee et al., 2010). Several groups have modeled pain-related cognitive impairment in animal models and demonstrated poor performance on delayed non-matching to position lever press tasks and delayed novel object recognition (Lindner et al., 1999; Millecamps et al., 2004; Hu et al., 2010). They describe this decreased accuracy, increased response latency for cognitively challenging tasks as the negative effects of pain on spatial learning, recognition, and memory (Hu et al., 2010). Neuropathic rat models are being analyzed to investigate the role of novel molecular therapeutic targets for chronic pain (Qian et al., 2019).

**Processing, Executive Functioning, and Decision Making**

Executive function is a set of neurological processes that assist with complex cognitive functions such as planning, organization, thought control, self-regulation, goal-directed actions, initiation, and analyses of actions (Moriarty et al., 2011). Emotional decision-making requires higher executive functioning (Tyng et al., 2017). Anatomically, executive functioning is a higher mental function regulated by the frontal lobes, including the dorsolateral prefrontal cortex (DLPC), ACC, orbitofrontal cortex (Verdejo-García et al., 2006). There is a functional overlap in the pathways in the brain responsible for executive functioning and pain perception. Gray matter reduction is implicated in age-related cognitive decline and an impaired executive functioning and decreased processing speed (Miñкова et al., 2017). These age-related gray matter changes are expedited in chronic pain syndromes. ACC, IC, and the DLPC are decreased in volume in patients with chronic pain (Ceko et al., 2013; Lai et al., 2020; Planchuelo-Gómez et al., 2020). Since these areas are also part of the pain neuromatrix, loss of these areas correlates with changes in cognitive executive functioning, and processing speed.
In the descending pain pathway, opioids act on the PAG, RVM, emotional, interoceptive, inferential, and cognitive information. The non-linearity of the intensity of the painful stimulus and the neurons that relay information to the thalamus and the PAG neurons of the DRG, excitatory interneurons, and lamina I to modify the perception of pain. This includes somatosensory associated with pain signaling and perception (Corder et al., 2018).

**Psychomotor Efficiency and Reaction Time**

Clinical studies in patients with chronic pain such as neuropathies have demonstrated that pain adversely impacts performance and psychomotor efficiency, and verbal reaction time (Ryan et al., 1993; Antepohl et al., 2003; Ryan, 2005; Shuchang et al., 2011). The number of pain sites and neuropathy duration is also positively correlated to psychomotor efficiency (Ryan, 2005). It is still unclear whether the intensity and nature of chronic pain syndrome impacts processing speed and attentional interference tasks. Animal models for inflammatory pain show impaired emotional decision-making on rodent gambling tasks (Pais-Vieira et al., 2009; Ji et al., 2010).

**THERAPIES FOR CHRONIC PAIN AND IMPACT ON COGNITION**

**Pharmacological Therapies**

Management of chronic pain remains a challenge for healthcare professionals. Apart from the treatment of inflammation using non-steroidal anti-inflammatory drugs, routinely used modalities for pain control target the sensory component of pain. The targets comprise of control of pain transmission [opioids and tricyclic antidepressants (TCAs)] and modulation of neuronal excitability (opioids, anticonvulsants) Figure 1.

Opioid receptors are uniquely present at all the neural loci associated with pain signaling and perception (Corder et al., 2018). The opioid system is well-positioned in the brain network to modify the perception of pain. This includes somatosensory neurons of the DRG, excitatory interneurons, and lamina I neurons that relay information to the thalamus and the PAG. The non-linearity of the intensity of the painful stimulus and the perception of pain result from the neural input from the sensory, emotional, interoceptive, inferential, and cognitive information. In the descending pain pathway, opioids act on the PAG, RVM, and spinal cord to modify the nociceptive input perception. Opioid analgesics also act at the level of the rostral, subcortical, and cortical sites, causing an analgesic impact by altering the body's affective and somatic responses (Corder et al., 2018).

Opioids have unique problems, including constipation, diarrhea, sedation, nausea, vomiting, and pruritus (Benyamin et al., 2008; Pask et al., 2020). Having said that, opioids remain the most preferred analgesic in the setting of chronic pain because of their high potency (Portenoy, 2011). Often patients on long-term therapy develop tolerance to the opioid medication, and higher doses are required to achieve the same therapeutic benefit (Anand et al., 2010). However, higher mean opioid consumption worsens distinct cognitive domains, in particular attention, language, orientation, and psychomotor function. Periodically follow-up with patients on chronic pain medications is essential to diagnose subtle cognitive changes (Pask et al., 2020). That said, the critical prespecified adverse events related to opioids, including addiction, depression, and particularly cognitive decline, are often not reported (Els et al., 2017). Evidence suggests that children born to opioid-dependent mothers tend to have a higher incidence of developing cognitive dysfunction, psychomotor disturbance, attention problems, and overall lower IQ as they grow up (Lee et al., 2020). Opioid-induced decreases in arousal are caused by blockade of cholinergic arousal projections from the brainstem to the thalamus and the cortex (Brown et al., 2018). Recent studies show a decrease in the gray matter volume and bilateral amygdalar modulation even with once-daily administration of morphine for 1 month (Lin et al., 2016). Mu opioid receptor and kappa-opioid receptor agonists have been shown to affect normal cognitive function; there is increased psychomotor retardation, decreased accuracy, and impaired recall. This bidirectional impact of pain and cognition has allowed researchers to test opioid antagonists as a potential cognitive-enhancing drug (Jacobson et al., 2018).

Although opioids, TCAs, and anticonvulsant therapies inherently impact the cognitive domains, this impact is inconsistently observed over human and animal studies. The majority of human studies suggest a decrease in attention, processing, memory encoding and retrieval, reaction time, and psychomotor performance with the use of opioids, TCAs, and anticonvulsants (Hindmarch et al., 2005; Sjøgren et al., 2005; Cherrier et al., 2009; Salinsky et al., 2010). However, evidence from some human studies and animal models is equivocal (Jamison et al., 2003; Tassain et al., 2003; Shannon and Love, 2004, 2005). Thus, analgesics in chronic pain and cognition studies can be a potential confounder that cannot be effectively controlled due to ethical reasons.

Endocannabinoids (ECs) are the in-built antinociceptive system of the body. Current research focuses on understanding this EC system better and maximizing its potential to provide safer pain control. The major areas of interest include – EC metabolism inhibition, Anandamide (AEA), and 1-arachidonoyl glycerol (2-AG) are the earliest recognized EC ligands in the body (Devane et al., 1992; Stella et al., 1997; Anand et al., 2010). ECs, AEA, and 2-AG, along with their enzyme modulators, fatty acid amide hydrolase and monoacylglycerol lipase, are essential components for modulation of pain perception and target of
most therapeutic interventions. Even though preclinical evidence suggests the role of opioid transmitters in causing cognitive decline, there is not enough evidence to indicate the role of ECs as a potential to decrease cognitive abilities (Woodhams et al., 2017). There is a growing interest in exploring the benefit of cannabis-derived products for managing chronic persistent pain (Wallace et al., 2015). However, it has been shown in recent studies that cannabis products increase the risk of depression and anxiety in adults experiencing chronic pain (Wildes et al., 2020).Thus, individualizing the analgesic therapy (type and dose) based on the patient's profile is essential for preventing pain and pain-related cognitive decline.

**Non-pharmacological Therapies**

Opioids are potent analgesics, however, considering their unique side effect profile and evidence of an emerging opioid epidemic, alternative non-pharmacological therapies are now being explored. Sensory processing of signals can be modulated by altering the attention component of cognitive processing (Petrovic et al., 2000). Modulation of the central sensory processing was successfully investigated by measuring regional cerebral blood flow with Positron Emission Tomography (PET) based technique during cognitively challenging tasks and with a painful stimulus (Petrovic et al., 2000). Neuroimaging studies PET and fMRI have shown a decreased pain perception with simple distraction techniques. This finding points toward the phenomenon of cortical suppression of pain in the presence of a cognitively challenging task. There were an observable increased signal intensity and activation of the cingulo-frontal cortex, including the orbitofrontal and perigenual ACC, as well as PAG and the posterior thalamus (Valet, 2004). This phenomenon is being translated into clinical practice by using innovative techniques such as virtual reality (VR) and augmented reality (AR) as a clinical tool for the management of pain (Pozeg et al., 2017; Pourmand et al., 2018; Chuan et al., 2020).

Cognitive behavior therapy refers to the psychotherapeutic techniques used to decrease pain perception. Traditionally, it includes relaxation therapy, activity pacing, sleep hygiene, scheduling pleasant activity, identifying and modifying cognitive distortions (Barrett et al., 2020). CBT has also shown promise in preventing acute pain conversion to chronic pain (Glare et al., 2020). Pain catastrophizing is a response style that impacts the outcomes of chronic pain patients. Pain catastrophizing is a maladaptive change, and patients often view pain as uncontrollable, permanent, and destructive. CBT is a vital treatment modality for this class of chronic pain patients (Day et al., 2020; Gilliam et al., 2020). Evidence in fibromyalgia patients suggests the clinical benefits of CBT in reducing pain catastrophizing (Lazaridou et al., 2017). Newer CBT methods, such as dialectic pain management (DPM), are being employed to improve and respond to chronic pain therapy (Barrett et al., 2020). DPM skill group sessions include a dialectic integration of change with acceptance to the present moment; this construct is further strengthened with mindfulness practices. Emotions, vulnerabilities, self-compassion, motivation, invalidation, and interpersonal effectiveness, and other personal challenges are addressed that commonly impact chronic pain patients (Barrett et al., 2020). Not just chronic pain, but therapies like acupuncture, hypnosis, mindfulness, relaxation, VR, and AR-based delivery system are being utilized for inpatient and outpatient acute pain such as headache, migraine, and pain in acute and emergency setting (Lindner et al., 2020; Vekhter et al., 2020). As a complementary procedure, acupuncture provides therapeutic benefits by increasing pain thresholds and insular activation (Cao et al., 2019).

Mindfulness meditation and mindfulness-based cognitive therapy have shown therapeutic benefit and improved sensitivity to opioid-based treatment in patients with chronic lower back pain (Zgierska et al., 2016; Day et al., 2019, 2020). Mindfulness-based practices focus on altering the pain catastrophizing, which is an essential component of non-pharmacological therapies for chronic pain. It alters the cognitive content, processing, and negative affectivity, thus leading to a shift critical for any treatment efficacy (Day et al., 2020). Other theoretical models hypothesize that mindful meditation can restructure the pain-related cognitive content, making adaptive changes necessary to counter pain perception. Studies have shown an increase in the EC levels even after short-term meditation practice, providing evidence of the analgesic potential of mind-body therapies (Sadhasivam et al., 2020). Understanding and individualizing the treatment and matching it to the patient's requirement can improve treatment response, adherence, and outcomes (Day et al., 2020; Zetterqvist et al., 2020). Considering at-home practices and online modules can improve reach and compliance with mindfulness-based therapies (Day et al., 2020; Zetterqvist et al., 2020).

**FUTURE DIRECTIONS**

Clinical and preclinical studies indicate a definitive link between pain and cognitive domains. However, the precise underlying psychological and neural mechanisms, the cognitive deficit associated with each chronic pain condition, and the role of subjective factors, the nature and the duration of the pain are yet to be elucidated. Chronic pain also results in adaptations and alterations in cognitive strategies, further adding to the heterogeneity in interpreting the primary deficit. Neuroplasticity-based reorganizational changes have an essential role in pain permanence and pain modulation and should be considered during the interpretation of the findings.

Lack of consistent cognitive effects across studies, methods, and pain conditions highlight the need for more standardized evaluation methods to allow comparisons to identify global and precise cognitive deficits. The use of different batteries of neurocognitive tests and pain questionnaires prevent a head-on comparison between different chronic pain conditions and their impact on the cognitive domains. The tests should have the sensitivity to identify the intensity of pain and the effect of pain on various cognitive domains. These limitations and the complex nature of the interconnection between pain and cognitive neuro-matrix makes evaluative conclusions rather difficult. Future studies should be designed to address these issues. Furthermore, current research lacks evidence...
to draw inference for longer-term impacts on cognition in patients with chronic pain. Chronic pain–based animal models have been used to understand the implication of pain on long term cognitive domains; however, these models are limited in their ability to mimic the motivation-affective and evaluative aspects of pain.

Future studies should be modified to incorporate psychophysiological, psychophysical, pharmacological, and brain imaging techniques to evaluate cognitive effects in the setting of chronic pain. Such studies would provide a multidimensional understanding of cognitive effects and provide insights into the underlying mechanisms and outcomes of pharmacotherapy. The current knowledge paves the way for future research to understand better the cognitive domains and their connection with various pain dimensions to improve therapeutic management and avoid unfavorable cognitive outcomes.

CONCLUSION

The past two decades have provided tremendous insights into the multifaceted role of pain in modulating cognitive domains and vice versa. This comprehensive review focused on the multidimensional role of pain in several cognitive domains including attention, memory, processing, executive functioning, decision making, psychomotor efficiency and reaction time highlights the current understanding of the intricate association between pain and cognition. We also provided insights into the role of various pharmacologic and non-pharmacologic approaches in the management of pain and the cognitive implications associated with it. It is imperative to understand the precise nature of the cognitive task affected by chronic pain. This understanding is crucial to tailor pain management therapy to the requirement of the individual. This personalized multimodal pain management allows improvement in long term quality of life and facilitates recovery.

REFERENCES

Al Mahrouqi, M. M., MacDonald, D. A., Vicenzino, B., and Smith, M. D. (2020). Quality of life, function and disability in individuals with chronic ankle symptoms: a cross-sectional online survey. J. Foot Ankle Res. 13:67. doi: 10.1186/s13047-020-00432-w
Alemanno, F., Houdayer, E., Emedoli, D., Locatelli, M., Mortini, P., Mandelli, C., et al. (2019). Efficacy of virtual reality to reduce chronic low back pain: proof-of-concept of a non-pharmacological approach on pain, quality of life, neuropsychological and functional outcome. PLoS One 14:e0216858. doi: 10.1371/journal.pone.0216858
Anand, K. J. S., Willson, D. F., Berger, J., Harrison, R., Meert, K. L., Zimmerman, J., et al. (2010). Tolerance and withdrawal from prolonged opioid use in critically ill children. Pediatrics 125, e1208–e1225. doi: 10.1542/peds.2009-0489
Antepohl, W., Kiviloo, L., Andersson, J., and Gerdl, B. (2003). Cognitive impairment in patients with chronic whiplash-associated disorder—a matched control study. Neurorehabilitation 18, 307–315
Apkarian, V. A., Sosa, Y., Krauss, B. R., Thomas, S. P., Fredrickson, B. E., Levy, R. E., et al. (2004). Chronic pain patients are impaired on an emotional decision-making task. Pain 108, 129–136. doi: 10.1016/j.pain.2003.12.015
Baddeley, A. (2010). Working memory. Curr. Biol. 20, R136–R140. doi: 10.1016/j.cub.2009.12.014
Barnhart, W. R., Buelow, M. T., and Trost, Z. (2019). Effects of acute pain and pain-related fear on risky decision-making and effort during cognitive tests. J. Clin. Exp. Neuropsychol. 41, 1033–1047. doi: 10.1080/13803395.2019.1646711
Barrett, D., Britzin, C. E., Zaski, A. M., and Edlund, M. J. (2020). Dialectical pain management: feasibility of a hybrid third-wave cognitive behavioral therapy approach for adults receiving opioids for chronic pain. Pain Med. doi: 10.1093/pm/pnaa361 [Epub ahead of print].
Basbaum, A. I., Bautista, D. M., Scherrer, G., and Julius, D. (2009). Cellular and molecular mechanisms of pain. Cell 139, 267–284. doi: 10.1016/j.cell.2009.09.028
Benyamin, R., Trescot, A. M., Datta, S., Buenaventura, R., Adlaka, R., Sehgal, N., et al. (2008). Opioid complications and side effects. Pain Physician 11(2 Suppl.), S105–S120.
Berryman, C., Stanton, T. R., Jane Bowering, K., Tabor, A., McFarlane, A., and Lorimer Moseley, G. (2013). Evidence for working memory deficits in chronic pain: a systematic review and meta-analysis. Pain 154, 1181–1196. doi: 10.1016/j.pain.2013.03.002

AUTHOR CONTRIBUTIONS

TK and VR: involve in the planning, critical thinking, and writing the manuscript. Both authors contributed to the article and approved the submitted version.

Bourne, S., Machado, A. G., and Nagel, S. J. (2014). Basic anatomy and physiology of pain pathways. Neurosurg. Clin. N. Am. 25, 629–638. doi: 10.1016/j.nec.2014.06.001
Boyette-Davis, J. A., Thompson, C. D., and Fuchs, P. N. (2008). Alterations in attentional mechanisms in response to acute inflammatory pain and morphine administration. Neuroscience 151, 558–563. doi: 10.1016/j.neuroscience.2007.10.032
Brown, E. N., Pavone, K. J., and Naranjo, M. (2018). Multimodal general anesthesia: theory and practice. Anesth. Analg. 127, 1246–1258. doi: 10.1213/ane.0000000000003668
Calandre, E. P., Bembibre, J., Arnedo, M. L., and Becerra, D. (2002). Cognitive disturbances and regional cerebral blood flow abnormalities in migraine patients: their relationship with the clinical manifestations of the illness. Cephalalgia 22, 291–302. doi: 10.1046/j.1468-2982.2002.00370.x
Cao, J., Tu, Y., Orr, S. P., Lang, C., Park, J., Vangel, M., et al. (2019). analgesic effects evoked by real and imagined acupuncture: a neuroimaging study. Cereb. Cortex 29, 3220–3231. doi: 10.1093/cercor/bhy190
Casey, K. L., and Lorena, J. (2000). The determinants of pain revisited: coordinates in sensory space. Pain Res. Manage. 5, 197–204. doi: 10.1155/2000/586814
Ceko, M., Bushnell, M. C., Fitzcharles, M.-A., and Scheinhardt, P. (2013). Fibromyalgia interacts with age to change the brain. NeuroImage Clin. 3, 249–260. doi: 10.1016/j.nicl.2013.08.015
Cherrier, M. M., Amory, J. K., Ersek, M., Risler, L., and Shen, D. D. (2009). Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults. J. Pain 10, 1038–1050. doi: 10.1016/j.jpain.2009.03.017
Chuan, A., Zhou, J. I., Hou, R. M., Stevens, C. J., and Bogdanovych, A. (2020). Virtual reality for acute and chronic pain management in adult patients: a narrative review. Anaesthesia 76, 695–704. doi: 10.1111/anae.15202
Corder, G., Castro, D. C., Bruchas, M. R., and Scherrer, G. (2018). Endogenous and exogenous opioids in pain. Annu. Rev. Neurosci. 41, 453–473. doi: 10.1146/annurev-neuro-080317-0-61522
Cousins, S., Ridsdale, L., Goldstein, L. H., Noble, A. J., Moorey, S., and Seed, P. (2015). A pilot study of cognitive behavioural therapy and relaxation for migraine headache: a randomised controlled trial. J. Neurol. 262, 2764–2772. doi: 10.1007/s00415-015-7916-z
Curatolo, M., La Bianca, G., Cosentino, G., Kaschi, R., Salemi, G., Talotta, R., et al. (2017). Motor cortex tRNS improves pain, affective and cognitive impairment in patients with fibromyalgia: preliminary results of a randomised sham-controlled trial. Clin. Exp. Rheumatol. 35(Suppl. 105), 100–105.
Day, M. A., Ward, L. C., Ehde, D. M., Thorn, B. E., Burns, J., Barnier, A., et al. (2019). A pilot randomized controlled trial comparing mindfulness meditation, cognitive therapy, and mindfulness-based cognitive therapy for chronic low back pain. *Pain Med.*, 20, 2134–2148. doi: 10.1093/pnm/npy273

Day, M. A., Ward, L. C., Thorn, B. E., Burns, J., Ehde, D. M., Barnier, A. I., et al. (2020). Mechanisms of mindfulness meditation, cognitive therapy, and mindfulness-based cognitive therapy for chronic low back pain. *Clin. J. Pain*, 36, 740–749. doi: 10.1097/AJP.0000000000000862

Devane, W. A., Breuer, A., Sheskin, T., Järbe, T. U., Eisen, M. S., and Mechoulam, R. (1999). Delayed effects of a task with a painful target. *J. Neurophysiol.* 82, 5451–5464. doi: 10.1152/jn.1999.82.9.5451

Hart, R. P., Martelli, M. F., and Zasler, N. D. (2000). Chronic pain and neuroimaging evidence. *J. Pain Symptom Manage.* 20, 391–401. doi: 10.1016/S0885-3924(00)00055-9

Gulyaeva, N. V. (2017). Molecular mechanisms of neuroplasticity: an expanding universe. *Biochemistry* 82, 237–244. doi: 10.1134/504691. doi: 10.1007/s00629-9717-0578-4

Devane, W. A., Breuer, A., Sheskin, T., Järbe, T. U., Eisen, M. S., and Mechoulam, R. (1999). Delayed effects of a task with a painful target. *J. Neurophysiol.* 82, 5451–5464. doi: 10.1152/jn.1999.82.9.5451

Hart, R. P., Martelli, M. F., and Zasler, N. D. (2000). Chronic pain and neuroimaging evidence. *J. Pain Symptom Manage.* 20, 391–401. doi: 10.1016/S0885-3924(00)00055-9

Gulyaeva, N. V. (2017). Molecular mechanisms of neuroplasticity: an expanding universe. *Biochemistry* 82, 237–244. doi: 10.1134/504691. doi: 10.1007/s00629-9717-0578-4

Hoegh, M., Seminowicz, D. A., and Graven-Nielsen, T. (2019). Delayed effects of a task with a painful target. *J. Neurophysiol.* 82, 5451–5464. doi: 10.1152/jn.1999.82.9.5451

Hindmarch, I., Trick, L., and Ridout, F. (2005). A double-blind, placebo- and positive-control-internalized (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. *Psychopharmacology* 183, 133–143. doi: 10.1007/s00213-005-0172-7

Huang, L., Dong, H. J., Wang, X., Wang, Y., and Xiao, Z. (2017). Duration and frequency of migraines affect cognitive function: evidence from neuropsychological tests and event-related potentials. *J. Headache Pain* 18:54. doi: 10.1186/s12104-017-0758-6

Iezzi, T., Archibald, Y., Barnett, P., Klink, A., and Duckworth, M. (1999). Neurocognitive performance and emotional status in chronic pain patients. *J. Behav. Med.* 22, 205–216. doi: 10.1023/A:1018791622441

Lee, S. J., Bora, S., Austin, N. C., Westerman, A., and Henderson, J. M. T. (2020). Cortical morphological changes in chronic migraine in a Taiwanese cohort: surface- and voxel-based analyses. *Cephalalgia* 40, 575–585. doi: 10.1080/03310458.2020.1863583

Lin, J. C., Chu, L. F., Stringer, E. A., Baker, K. S., Sayyid, Z. N., Sun, J., et al. (2015). Neuroplasticity underlying the development of chronic widespread pain: Where cells, systems and society meet. *Chir. Ital.* 11, 56–61. doi: 10.1186/s12880-015-0011-7

Lee, D. M., Pendleton, N., Tajar, A., O’Connor, D. B., Bartfai, G., et al. (2010). Chronic widespread pain is associated with slower cognitive processing speed in middle-aged and older European men. *Pain* 151, 30–36. doi: 10.1016/j.pain.2010.04.024

Lee, J. C., Chu, L. F., Stringer, E. A., Baker, K. S., Sayyid, Z. N., Sun, J., et al. (2016). One Month of Oral Morphine Decreases Gray Matter Volume in the Right Amygdala of Individuals with Low Back Pain: confirmation of Previously Reported Magnetic Resonance Imaging Results. *Pain Med.* 17, 1497–1504. doi: 10.1093/pm/pnv047
Lindner, M. D., Plone, M. A., Francis, J. M., and Cair, C. K. (1999). Chronic morphine reduces pain-related disability in a rodent model of chronic, inflammatory pain. Exp. Clin. Psychopharmacol. 7, 187–197. doi: 10.1037/1064-1297.7.3.187

Lindner, S., Latoschik, M.-E., and Rittner, H. (2020). Use of Virtual Reality as a Component of Acute and Chronic Pain Treatment. Anesthesiol. Intensivmed. Notfallmed. Schmerzther. 55, 549–561. doi: 10.1055/a-2202-3038

Martinsen, S., Flodin, P., Berrebi, J., Löpfren, M., Bileviciute-Ljungar, I., Mannerkorpi, K., et al. (2018). The role of long-term physical exercise on performance and brain activation during the Stroop colour word task in fibromyalgia patients. Clin. Physiol. Funct. Imaging 38, 508–516. doi: 10.1111/cpf.12449

McCracken, L. M., and Iverson, G. L. (2001). Predicting complaints of impaired cognitive functioning in patients with chronic pain. J. Pain Symptom Manage. 21, 392–396. doi: 10.1016/S0885-3924(01)00267-6

McGuire, B. E. (2013). Chronic pain and cognitive function. Pain 154, 946–965. doi: 10.1016/j.pain.2013.04.008

Melzack, R., Coderre, T. J., Katz, J., and Vaccarino, A. L. (2006). Central pain. Facts Views: Sci. Am. 254, 104–122. doi: 10.1016/S0069-4016(06)70002-5

Milleccamps, M., Etienne, M., Jourdan, D., Eschalier, A., and Ardid, D. (2004). Decrease in non-selective, non-sustained attention induced by a chronic visceral inflammatory state as a new pain evaluation in rats. Pain 109, 214–224. doi: 10.1016/j.pain.2003.12.028

Minkova, L., Habich, A., Peter, J., Kaller, C. P., Eickhoff, S. B., and Klöppel, S. (2017). Gray matter asymmetries in aging and neurodegeneration: a review and meta-analysis. Hum. Brain Mapp. 38, 5890–5904.

Mirsy, A. F., Anthony, B. J., Duncan, C. C., Ahearn, M. B., and Bellam, S. G. (1991). Analysis of the elements of attention: a neuropsychological approach. Neuropsychol. Rev. 2, 109–145. doi: 10.1007/BF01109051

Moriarty, O., McGuire, B. E., and Finn, D. P. (2011). The effect of pain on cognitive function: a review of clinical and preclinical research. Prog. Neurobiol. 93, 385–404. doi: 10.1016/j.pneurobiol.2011.01.002

Müller, H. (2000). [Neuroplasticity and chronic pain], Anesthesiol. Intensivmed. Notfallmed. Schmerzther. 35, 274–284. doi: 10.1055/s-2000-252

Muñoz, M., and Esteve, R. (2005). Reports of memory functioning by patients with chronic pain. Clin. J. Pain 21, 287–291. doi: 10.1097/01.ajp.0000173993.57373.2e

Mutso, A. A., Radzicki, D., Baliki, M. N., Huang, L., Banisadr, G., Centeno, M. V., et al. (2012). Abnormalities in hippocampal functioning with persistent pain. J. Neurosci. 32, 5747–5756. doi: 10.1523/JNEUROSCI.0587-12.2012

Najib, S. M., Jarem, Z., and Manee, F. S. (2016). The cognitive functions in adults with chronic pain: a comparative study. Pain Res. Manage. 2016, 5719380. doi: 10.1155/2016/5719380

Neugebauer, V. (2015). Amygdala pain mechanisms. Handb. Exp. Pharmacol. 227, 261–284. doi: 10.1007/978-3-662-46450-2_13

Neugebauer, V., Li, W., Bird, G. C., and Han, J. S. (2004). The amygdala is involved in the control processes, “ in Human Memory, eds C. Atkinson and M. Shiffrin (New York, NY: Psychology Press). 10.1007/0-8247-4266-5

Qian, Y., Xia, T., Cui, Y., Chu, S., Ma, Z., and Gu, X. (2019). The role of CaMKII in neuropathic pain and fear memory in chronic constriction injury in rats. Int. J. Neurosci. 129, 146–154. doi: 10.1080/00207454.2018.1512986

Raja, S. N., Carr, D. B., Cohen, M., Finnerup, N. B., Flor, H., Gibson, S., et al. (2020). The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain 161, 1976–1982. doi: 10.1016/j.pain.2020.01.039

Ramachandran, V. S., and Rogers-Ramachandran, D. (2000). Phantom limbs and neural plasticity. Arch. Neurol. 57, 317–320. doi: 10.1001/archneur.57.3.317

Risch, K. M., González-Roldán, A. M., Montoya, P., Glig, S., Anton, F., and van der Meulen, M. (2020). Distraction from pain: the role of selective attention and pain catastrophizing. Eur. J. Pain 24, 1880–1891. doi: 10.1016/j.ejp.1634

Rodríguez-Andreu, J., Ibáñez-Bosch, R., Portero-Vázquez, A., Masramon, X., Rejas, J., and Gálvez, R. (2009). Cognitive impairment in patients with fibromyalgia syndrome as assessed by the mini–mental state examination. BMC Musculoskelet. Disord. 10:162. doi: 10.1186/1471-2474-10-162

Roozendaal, B., Okuda, S., de Quervain, D. J.-F., and McGaugh, J. L. (2006). Glucocorticoids interact with emotion-induced noradrenergic activation in influencing different memory functions. Neuroscience 138, 901–910. doi: 10.1016/j.neuroscience.2005.07.049

Ryan, C. M. (2003). Diabetes, aging, and cognitive decline. Neurobiol. Aging 26(Suppl. 1), 21–25. doi: 10.1016/j.neurobiolaging.2005.09.006

Ryan, C. M., Williams, T. M., Finegold, D. N., and Orchard, T. J. (1993). Cognitive dysfunction in adults with type 1 (insulin-dependent) diabetes mellitus of long duration: effects of recurrent hypoglycemia and other chronic complications. Diabetologia 36, 329–334. doi: 10.1007/BF00004236

Sadhasivam, S., Alankar, S., Maturi, R., Vishnubhotla, R. V., Madigonda, M., Pawale, D., et al. (2020). Inner engineering practices and advanced 4-day Isla yoga retreat are associated with cannabinimetic effects with increased endocannabinoids and short-term and sustained improvement in mental health: a prospective observational study of meditators. Evid. Based Complement. Alternat. Med. 2020:8438272. doi: 10.1155/2020/8438272

Sayd, F. A., Betoni, T. B., Magalhães, V., Nishihara, R., and Skare, T. L. (2019). Rheumatoid arthritis and cognition dysfunction: lack of association with cumulative glucocorticoid use. Immunopharmacol. Immunotoxicol. 41, 565–567. doi: 10.1080/08929737.2019.1679170

Salmuk, M., Storbach, D., and Munoz, S. (2010). Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial. Neurology 74, 755–761. doi: 10.1212/WNL.0b013e3181d52534

Sawangjit, A., Oyanedel, C. N., Niethard, N., Salazar, C., Born, J., and Inostroza, M. (2018). The hippocampus is crucial for forming non-hippocampal long-term memory during sleep. Nature 564, 109–113. doi: 10.1038/s41586-018-0716-8

Shannon, H. E., and Love, P. L. (2004). Effects of antiepileptic drugs on working memory as assessed by spatial alternation performance in rats. Epilepsy Behav. 5, 857–865. doi: 10.1016/j.yebeh.2004.08.017

Shannon, H. E., and Love, P. L. (2005). Effects of antiepileptic drugs on attention as assessed by a five-choice serial reaction time task in rats. Epilepsy Behav. 7, 620–628. doi: 10.1016/j.yebeh.2005.08.017

Shiffrin, R. M. (1977). “Commentary on “human memory: a proposed system and its control processes,” in Human Memory, eds C. Atkinson and M. Shiffrin (New York, NY: Psychology Press). 10.1007/0-8247-4266-5
Shiffrin Richard (Amsterdam: Elsevier), 1–5. doi: 10.1016/b978-0-12-121050-2.25005-3
Shuchang, H., Mingwei, H., Hongxiao, J., Si, W., Xing, Y., Antonius, D., et al. (2011). Emotional and neurobehavioural status in chronic pain patients. Pain Res. Manage. 16, 41–43. doi: 10.1155/2011/825636
Sjøgren, P., Christrup, L. L., Petersen, M. A., and Højsted, J. (2005). Neuropsychological assessment of chronic non-malignant pain patients treated in a multidisciplinary pain centre. Eur. J. Pain 9, 453–462. doi: 10.1016/j.ejpain.2004.10.005
Sloan, P., and Hollins, M. (2017). Attention and pain: are auditory distractors feasible of behavioral treatments for migraine, headache, and pain in the acute setting. Curr. Pain Headache Rep. 24:66. doi: 10.1007/s11916-020-00899-z
Verdejo-García, A., Bechara, A., Recknor, E. C., and Pérez-García, M. (2006). Executive dysfunction in substance dependent individuals during drug use and abstinence: an examination of the behavioral, cognitive and emotional correlates of addiction. J. Int. Neuropsychol. Soc. 12, 405–415. doi: 10.1017/S1355617706006486
Verdejo-García, A., López-Torrecillas, F., Calandre, E. P., Delgado-Rodríguez, A., and Rechera, A. (2009). Executive function and decision-making in women with fibromyalgia. Arch. Clin. Neuropsychol. 24, 113–122. doi: 10.1093/acin/acp014
Villelure, C., and Bushnell, M. C. (2002). Cognitive modulation of pain: how do attention and emotion influence pain processing? Pain 95, 195–199. doi: 10.1016/s0304-3959(02)00077-0
Wager, T. D., Atlas, L. Y., Lindquist, M. A., Roy, M., Woo, C.-W., and Kross, E. (2013). An fMRI-based neurologic signature of physical pain. N. Engl. J. Med. 368, 1388–1397. doi: 10.1056/NEJMoa1204471
Walanker, P. P., Panvale, P. V., and Patil, M. M. (2020). Psychosocial factors, disability and quality of life in chronic shoulder pain patients with central sensitization. Health Psychol. Res. 8:8874. doi: 10.4081/hpr.2020.8874
Wallace, M. S., Marcotte, T. D., Umlauf, A., Gouaux, B., and Atkinson, J. H. (2015). Efficacy of inhaled cannabis on painful diabetic neuropathy. J. Pain 16, 616–627. doi: 10.1016/j.jpain.2015.03.008
Weiner, D. K., Rudy, T. E., Morrow, L., Slaboda, J., and Lieber, S. (2006). The relationship between pain, neuropyschological performance, and physical function in community-dwelling older adults with chronic low back pain. Pain Med. 7, 60–70. doi: 10.1111/j.1526-4637.2006.00091.x
Wilders-Smith, O. H. (1995). [Pre-emptive analgesia]. Anaesthesist 44(Suppl. 3), S29–S534.
Wildes, M., Bigand, T. L., Layton, M. E., and Wilson, M. (2020). Cannabis use and cognition in adult patients prescribed opioids for persistent pain. Pain Manage. Nurs. 21, 94–99. doi: 10.1016/j.pmn.2019.06.014
Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., and Neugebauer, V. (2017). The cannabinoid system and pain. Neuropharmacology 124, 105–120. doi: 10.1016/j.neuropharm.2017.06.015
Xie, Y.-F., Huo, F.-Q., and Tang, J.-S. (2009). Cerebral cortex modulation of pain. Acta Pharmacol. Sin. 30, 31–41. doi: 10.1038/aps.2008.14
Yam, M., Loh, Y., Tan, C., Adam, S. K., Manan, N. A., and Basir, R. (2018). General pathways of pain sensation and the major neurotransmitters involved in pain regulation. Int. J. Mol. Sci. 19:2164. doi: 10.3390/ijms19082164
Zalel, I., Filipović, D., and Puškaš, N. (2016). Chronic stress, hippocampus and parvalbumin-positive interneurons: What do we know so far? Rev. Neurosci. 27, 397–409
Zetterqvist, V., Gentili, C., Rickardsson, J., Sörensen, I., and Wicksell, R. K. (2020). Chronic Pain and Attention in Older Community-Dwelling Adults. J. Am. Geriatr. Soc. 66, 1318–1324. doi: 10.1111/jgs.15413
Zvierska, A. E., Burzinski, C. A., Cox, J., Kloke, J., Stegner, A., Cook, D. B., et al. (2020). Mindfulness meditation and cognitive behavioral therapy intervention for chronic pain and their parents: a nonrandomized pilot trial. J. Pediatr. Psychol. 44(Suppl. 3), 30, 31ñ41. doi: 10.1038/aps.2008.14
Zimmermann, H., Ming, R., Wittenmark, E., and Kofman, S. (2009). The role of the somatosensory cortex in the modulation of pain. Neuropharmacology 57, 399–408. doi: 10.1016/j.neuropharm.2009.03.020
Zimmermann, H., Ming, R., Wittenmark, E., and Kofman, S. (2009). The role of the somatosensory cortex in the modulation of pain. Neuropharmacology 57, 399–408. doi: 10.1016/j.neuropharm.2009.03.020
Zimmermann, H., Ming, R., Wittenmark, E., and Kofman, S. (2009). The role of the somatosensory cortex in the modulation of pain. Neuropharmacology 57, 399–408. doi: 10.1016/j.neuropharm.2009.03.020
Zimmermann, H., Ming, R., Wittenmark, E., and Kofman, S. (2009). The role of the somatosensory cortex in the modulation of pain. Neuropharmacology 57, 399–408. doi: 10.1016/j.neuropharm.2009.03.020
Zimmermann, H., Ming, R., Wittenmark, E., and Kofman, S. (2009). The role of the somatosensory cortex in the modulation of pain. Neuropharmacology 57, 399–408. doi: 10.1016/j.neuropharm.2009.03.020
Zimmermann, H., Ming, R., Wittenmark, E., and Kofman, S. (2009). The role of the somatosensory cortex in the modulation of pain. Neuropharmacology 57, 399–408. doi: 10.1016/j.neuropharm.2009.03.020